Research Reveals Unique Properties of Vitro’s Fluorescent Stem Cells

GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced completion of a research report concerning its fluorescent stem cells, http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf. This report revealed transfer of fluorescent to differentiated cells including chondrocytes, cells responsible for making cartilage. Fluorescent stem cells allow tracking of stem cells following transplantation and studies of stem cell homing or migration to cancer stem cells, sites of cellular injury or inflammation. This work may lead to new developments for targeting drug delivery and stem cell therapy. Vitro Biopharma’s new research shows that its fluorescent stem cells also have application to studies of stem cell differentiation and thus to expanded investigations of the therapeutic uses of stem cells.

“Tools for Stem Cell and Drug Development™”

Vitro Biopharma supplies three different kinds of fluorescent stem cell lines labeled by different methods and fluorescent probes, including both green and red fluorescent stem cells. Another stem cell type offered by Vitro Biopharma is labeled with green fluorescent protein, a commonly used marker in biological research. The new research shows that not only do stem cells retain fluorescence, but the fluorescent label is also transferred to differentiated cells including chondrocytes. Red fluorescent-labeled stem cells showed enhanced fluorescence of differentiated cells indicating further applications of this stem cell line for use in the advancement of stem cell technology.

Dr. Jim Musick, Vitro’s CEO said, “We are pleased to report our research showing application of our fluorescent stem cells to not only to stem cell localization, but also to stem cell differentiation. This new development allows expanded uses of our fluorescent stem cells, which to our knowledge are not available from other vendors. We hope that our products for stem cell research and drug development will contribute to the advancement of stem cell therapy to conditions without prior treatment options including not only degenerative diseases but also aggressive forms of poor prognosis cancer.”

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc., dba Vitro Biopharma (OTCBB: VODG) (http://www.vitrobiopharma.com), known for “Harnessing the Power of Cells,” owns U.S. patents for production of FSH, a fertility drug, immortalization of cells, and adult stem cells. The Company also owns a pending U.S. patent regarding stem cell-based cancer treatments and is continuously developing newly patentable cell lines and technologies. Vitro recently established a new high-tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. We manufacture and sell “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, and products supporting induced pluripotent stem cell and cancer research.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.